PCSK9 Mutations

PCSK9 Loss-of-function Mutations

2013 ACC/AHA Cholesterol Guidelines 4 Major Statin Benefit Groups

PCSK9 Monoclonal Antibodies

MENDEL Evolocumab Monotherapy for Hypercholesterolemia

LAPLACE-2 Study Design

LAPLACE-2 LDL-C Response at Mean of Weeks 10 and 12

GAUSS-2 Percent Change in LDL-C From Baseline at Week 12 in Statin-Intolerant Patients

DESCARTES Percent Change in LDL-C From Baseline at Week 52 in Patients With Hypercholesterolemia

DESCARTES Evolocumab Safety at 52 weeks

PCSK9 CV OutcomesTrials

Abbreviations

Abbreviations (cont)

References

References (cont)

References (cont)